Colette Shen, MD, PhD

University of North Carolina School of Medicine & Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Disclosures:

Presentations

Sep 29

245 - Phase I Dose Escalation/Dose Expansion Trial of NBTXR3/SBRT in Combination with Nivolumab or Pembrolizumab for the Treatment of anti-PD-1 Naïve or Resistant Patients with Recurrent/Metastatic Head and

03:40pm - 03:50pm PT